Table 1 Proportions of observed numbers of cases in 1993–97 covered by prediction intervals based on trends up to 1987, by site, sex, country and frequency*.
From: Empirical evaluation of prediction intervals for cancer incidence
Number of intervals | Coverage number (%) | P-value for difference | |
|---|---|---|---|
Site | 0.54 | ||
Lip | 5 | 2 (40) | |
Tongue, oral cavity and pharynx | 10 | 5 (50) | |
Oesophagus | 10 | 5 (50) | |
Stomach | 10 | 5 (50) | |
Colon | 10 | 7 (70) | |
Rectum | 10 | 5 (50) | |
Pancreas | 10 | 6 (60) | |
Larynx | 5 | 3 (60) | |
Lung | 10 | 4 (40) | |
Breast | 5 | 2 (40) | |
Cervix uteri | 5 | 2 (40) | |
Corpus uteri | 5 | 2 (40) | |
Ovary | 5 | 1 (20) | |
Prostate | 5 | 2 (40) | |
Testis | 5 | 4 (80) | |
Kidney | 10 | 7 (70) | |
Urinary bladder | 10 | 5 (50) | |
Melanoma of the skin | 10 | 3 (30) | |
Thyroid | 10 | 7 (70) | |
Non-Hodgkin lymphomas | 10 | 4 (40) | |
Hodgkin disease | 10 | 9 (90) | |
Multiple myeloma | 10 | 4 (40) | |
Acute leukaemia | 10 | 7 (70) | |
Other sites | 10 | 3 (30) | |
Sex | 0.67 | ||
Male | 100 | 50 (50) | |
Female | 100 | 54 (54) | |
Country | <0.001 | ||
Denmark | 40 | 18 (45) | |
Finland | 40 | 21 (53) | |
Iceland | 40 | 35 (88) | |
Norway | 40 | 20 (50) | |
Sweden | 40 | 10 (25) | |
Frequency | <0.001 | ||
≤ 70 per year | 50 | 42 (84) | |
> 70 and ≤ 230 per year | 50 | 26 (52) | |
> 230 and ≤ 555 per year | 50 | 23 (46) | |
> 555 per year | 50 | 13 (26) |